Swab Kits Vtm Utm Pcr Suppliers and Manufacturers

PCR Swabs Red Medium Clear Medium VTM UTM

Niosh N95, 3 Ply Surgical Masks, Kn95 Cdc / Fda / Ce / Whitelist / Appendix A, Surgical Gowns Level 1 4, Flocked Nasal Swab Kits, Utm/vtm Kits For Pcr, Covid 19 Test Kit, Rapid Test Kit, Ethanol Usp 190 Proof, Ethyl Alcohol.

Disposable Sterile Nylon Flocked Collection Swab With Virus Transport Medium This product is mainly composed of flocked swab, virus transport medium, virus transport medium tube. It is mainly used for collection, transportation and preservation of oropharyngeal parts of respiratory and enteric virus such as influenza, bird flu, hand-foot-mouth disease, swine flu and so on. It is also suitable for the collection of other viruses, chlamydia, mycoplasma and ureaplasma urealyticum specimen. Nylon flocked swab: Nylon flocked head , ABS stick ,incision, EO Sterile --Swab head are made of safe materials with superior quality to the national standard, maximizing the collection and release of samples. --Swab rod are made of special easily broken materials that will not result in micro debris. Features ----Higher sampling rate ----Faster and complete release of samples ----Enhance diagnostic sensitivity ----Convenient handling and transportation Size: 10ml / 5ml / 2ml etc..

Medical, surgical, industrial and paper products & chemicals.

CE-IVD, FDA certified kits

RT PCR-Detection Kit

Clinical VTM (Viral Transport Medium) for collection and transport of clinical specimen containing COVID-19 (Corona Virus) and others. Specification - Clinical Viral Transport Medium Manufacturer: Wizchem Unit - Kit (each) Unit Price - $1.80 per kit

This product is used for sample collection, transportation and storage, such as the samples collection of SARS-CoV-2 oropharyngeal swabs.

The Kit follows a magnetic bead-based approach for the rapid and reliable isolation of viral RNA/DNA from nasopharyngeal (NP) swab specimens that are dry or in viral transport media (VTM). Description The Kit follows a magnetic bead-based approach for the rapid and reliable isolation of viral RNA/DNA from nasopharyngeal (NP) swab specimens that are dry or in viral transport media (VTM). The extraction methodology is easily adaptable to various automated systems and can also be scaled up or down depending on the amount of starting sample amount used. The kit enables purification of high-quality nucleic acids that are free of proteins, nucleases, and other impurities. Nucleic acid isolated by the kit is stable with good integrity and purity, and can be directly used in downstream molecular biology experiments such as PCR and real time qPCR, and next generation sequencing. Keys *  Magnetic bead-based purification * High-quality nucleic acid can be obtained range from 10 min to 40min (up to different protocol). * High throughput: Can be integrated with magnetic rod method automatic instrument or pipetting method automatic instrument to carry out high throughput extraction experiment. *  Safe and nontoxic: No toxic organic reagents such as phenol/chloroform are needed. *  Complete removal of contaminants and PCR inhibitors for downstream experiments. Features Specification Starting Amount - 200ul Starting Material - swab specimens or in viral transport media (VTM). Elution Volume - 80-150L Technology - Magnetic bead-based purification technology Processing Mode - Manual or Auto Throughput - 32/48/96/192 samples/run(up to different machine). Storage - Room temperature (15-25) Applications PCR and real time qPCR, and next generation sequencing.

Taq DNA Polymerase Carmine Taq PCR Master Mix (With Dye) 2X Taq PCR Smart Mix without dye

Viral Transport Medium (VTM) Kit specigrab Viral transport medium for COVID-19. 3mL of Media in a sterilized tube with two swabs in a kit Features 1) Easy to use 2) Flexible Transport Temperature Ranges 3) Long-term preservation 4) Cost-efficient

CAT No : STRUVTM01. Viral Tranport Medium (VTM) Kit: 50 Test Tubes 100 Swabs (Oral & Nasal)

Viral transport medium is used to carry the patient samples to test in RTPCR testing.

Product: KN95 (FDA, CDC APPENDIX A) Price: $0.40 with FREE Delivery anywhere in USA Quantity: 4 million Location: Los Angeles Brand: Chengde Technology MOQ: 1 million SOP: PO --> Inspect and Pay Use to sell these to Texas Hospitals for $2.35 each in June.

Our test kit has been approved and endorsed by Singapore's MOH (Ministry of Health) and HSA (Health Science Authority) since last year and we have been constantly supplying to the APAC countries during this period. (Japan, India, Singapore, Malaysia, Indonesia and etc.) * CE mark was attained in December 2020. * Our Tepat 1.0 SARS-CoV-2 RT-PCR provides for high-throughput, sensitive and specific detection of SARS-CoV-2 RNA extracted from nasopharyngeal swabs*. It can detect 6 copies of viral RNA per reaction with > 95% confidence. Clinical validation shows 100% sensitivity, with no cross-reaction with non-SARS-CoV-2 species. Key Highlights 1.5 hours from RNA to results Multiplex RdRp and M viral genes detection enhances sensitivity and specificity 100% coverage with 100% identity of all SARS-CoV-2 genomes in the world Detects 6 copies of viral RNA Whole process control: human RNase P

SARS COV-2 VARIANTS REAL TIME KIT 5 targets. One single reaction tube per sample. Identification of the main SARS Cov-2 variants of concern, UK, South Africa, Brazil, Nigeria, Indian (Delta). Rapid qualitative detection, 45 minutes. Certified CE IVD Full furniture directly.

The COVID-19 RT-PCR Detection Kit is a real-time RT-PCR test intended for the qualitative detection of nucleic acid from the SARS-CoV-2 in upper and lower respiratory specimens (such as anterior nasal swabs, mid-turbinate nasal swabs, nasopharyngeal swabs, oropharyngeal swabs, sputum, lower respiratory tract aspirates, bronchoalveolar lavage, and nasopharyngeal wash/aspirate or nasal aspirate) from individuals suspected of COVID-19 by their healthcare provider. Testing is limited to laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) of 1988, 42 U.S.C. 263a, to perform high complexity tests. Results are for the identification of SARS-CoV-2 RNA. The SARS-CoV-2 RNA is generally detectable in upper and lower respiratory specimens during the acute phase of infection. Positive results are indicative of the presence of SARS-CoV-2 RNA; clinical correlation with patient history and other diagnostic information is necessary to determine patient infective status. The agent detected may not be the definite cause of disease. Positive results do not rule out bacterial co-infection with other viruses. Laboratories within the United States and its territories are required to report all positive results to the appropriate public health authorities. Negative results do not preclude SARS-CoV-2 infection and should not be used as the sole basis for patient management decisions. Negative results must be combined with clinical observations, patient history, and epidemiological information. The COVID-19 RT-PCR Detection Kit is intended for use by qualified trained clinical laboratory personnel specifically instructed and trained in the techniques of real-time PCR and in vitro diagnostic procedures. The COVID-19 RT-PCR Detection Kit is only for use under the Food and Drug Administration's Emergency Use Authorization. PRINCIPLE OF DETECTION This product is a fluorescent probe-based Taqman RT-PCR assay system. Firstly, the RNA of SARS-CoV-2 will be reverse transcribed into cDNA by reverse transcriptase, and then PCR amplification will be performed with cDNA as template. During amplification of the template, the TaqMan probe will be degraded due to the 5'-3 polymerase activity and exonuclease activity of Taq DNA polymerase, then the separation of fluorescent reporter and quencher enables the fluorescent signal to be detected by instrument. The ORF1ab gene of SARS-CoV-2 will be detected qualitatively by FAM channel, the N gene of SARS-CoV-2 will be detected qualitatively by JOE channel, the E gene of SARS-CoV-2 will be detected qualitatively by ROX channel, and the internal reference will be detected by CY5 channel. dUTP and UNG enzyme are used in the kit to prevent contamination of the amplified products. Internal reference is used in the kit for quality control starting from sample collection

Indication: Qualitative detection of nucleic acid from SARS-CoV-2 in upper and lower respiratory specimens (such as anterior nasal swabs, mid-turbinate nasal swabs, nasopharyngeal swabs, oropharyngeal swabs, sputum, lower respiratory tract aspirates, bronchoalveolar lavage, and nasopharyngeal wash/aspirate or nasal aspirate) from individuals suspected of COVID-19 by their healthcare provider. Emergency use of this test is limited to authorized laboratories. Authorized Laboratories: Laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. 263a, to perform high complexity tests. This letter is in response to your1 request that the Food and Drug Administration (FDA) issue an Emergency Use Authorization (EUA) for emergency use of your product,2 pursuant to Section 564 of the Federal Food, Drug, and Cosmetic Act (the Act) (21 U.S.C. 360bbb-3). On February 4, 2020, pursuant to Section 564(b)(1)(C) of the Act, the Secretary of the Department of Health and Human Services (HHS) determined that there is a public health emergency that has a significant potential to affect national security or the health and security of United States citizens living abroad, and that involves the virus that causes COVID-19. Pursuant to Section 564 of the Act, and on the basis of such determination, the Secretary of HHS then declared that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of the virus that causes COVID-19 subject to the terms of any authorization issued under Section 564(a) of the Act. Having concluded that the criteria for issuance of this authorization under Section 564(c) of the Act are met, I am authorizing the emergency use of your product, described in the Scope of Authorization of this letter (Section II), subject to the terms of this authorization. I. Criteria for Issuance of Authorization I have concluded that the emergency use of your product meets the criteria for issuance of an authorization under Section 564(c) of the Act, because I have concluded that: 1. The SARS-CoV-2 can cause a serious or life-threatening disease or condition, including severe respiratory illness, to humans infected by this virus; 2. Based on the totality of scientific evidence available to FDA, it is reasonable to believe that your product may be effective in diagnosing COVID-19, and that the known and potential benefits of your product when used for diagnosing COVID-19, outweigh the known and potential risks of your product; and, 3. There is no adequate, approved, and available alternative to the emergency use of your product. 4 II. Scope of Authorization I have concluded, pursuant to Section 564(d)(1) of the Act, that the scope of this authorization is limited to the indication above.